Protalix BioTherapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.2M | $21.1M | $9.2M | $4.4M | $3.5M | $0 | $34.9M | $8.4M |
| Cost of Revenue | $9.3M | $15.2M | $8.4M | $730.0K | $630.0K | $0 | $8.1M | $1.5M |
| Gross Profit | $24.9M | $4.0M | $801.0K | $3.6M | $2.9M | $0 | $26.3M | $1.4M |
| Gross Margin | 72.8% | 19.0% | 8.7% | 83.3% | 82.1% | — | 75.4% | 17.2% |
| Operating Expenses | ||||||||
| Research & Development | $33.3M | $32.2M | $30.4M | $24.9M | $27.4M | $29.2M | $36.7M | $37.8M |
| SG&A Expense | $10.9M | $11.5M | $9.4M | $7.3M | $9.2M | $8.1M | $9.8M | $6.9M |
| Operating Income | $-19.3M | $-34.5M | $-33.2M | $-23.7M | $-28.6M | $-34.1M | $-12.2M | $-36.5M |
| Operating Margin | -56.4% | -163.8% | -360.5% | -542.4% | -810.6% | — | -34.9% | -435.6% |
| Interest Expense | — | — | — | $3.5M | $3.5M | $1.0M | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-26.5M | $-83.4M | $-29.4M | $58.0M | $-29.9M | $-27.8M | $-11.6M | $-36.5M |
| Net Margin | -77.3% | -395.9% | -319.2% | 1,329.9% | -849.9% | — | -33.3% | -435.6% |
| EPS (Basic) | $-1.80 | $-6.37 | $-0.29 | $0.61 | $-0.32 | $-0.30 | $-0.13 | $-0.43 |
| EPS (Diluted) | $-1.80 | $-6.37 | $-0.29 | $0.61 | $-0.32 | $-0.30 | $-0.13 | $-0.43 |
| Shares Outstanding (Basic) | 14.8M | 143.7M | 124.1M | 99.8M | 93.6M | 93.6M | 93.5M | 85.6M |
| Shares Outstanding (Diluted) | 14.8M | 143.7M | 124.1M | 99.8M | 93.6M | 93.6M | 93.5M | 85.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |